Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment refractory bipolar disorder. Am J Psychiatry 1999; 156:1019.
Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60:79.
Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. Affect Disord 1998; 50:245.
Young LT, Robb JC, Hasey GM, et al. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999; 55:73.
.
Ghaemi SN, Goodwin FK. Use of atypical agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999; 12(suppl):57.
Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50:245.
Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156:1164.
Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56:407.
Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702.
5. .
, , , . (. 5.1). , ( )[58], , . 1960 . ; 40- , ; 50- , .
5.1.
() | () | () | |
(, .) | 0,25; 0,5; 1,0;2,0 () | 0,5; 1 ** () | |
* () | 5; 10 () | ||
** ( .) | 25 () | ||
(, , , .) | 2; 5; 10 (, **) 5; 10/2,5 ** ( . ) | 15* | 10 /2 *; 5 /2 ** (. .*) 50 /10 ()* |
∆ (*, , .) | 5; 10 () | ||
**∆ (, , .) | 7,5 () | ||
*∆ () | 7,5; 15,0 () | ||
(*, , , ) | 0,25**; 0,5; 1,0; 2,0 () 2,5 /** ( ) | 1 /2 ** () | |
( .) | 3,75; 7,5; 15,0 ()* 3,75; 5,0; 7,5; 10; 15** () | 11,25; 22,5* | |
(*, , .) | 0,5*; 1,0; 2,0; 2,5** (, **) | 20 /10 *, 40 /10 * () 2 /*; 4 /* () | |
**☼ (, ) | 10,0 () | ||
** () | 200; 400 () | ||
∆ (*, , ) | 7,5**; 15** () | 1 /; 3 /**; 5 / (, *) | |
**∆ (, .) | 5,0; 10,0 () | ||
(, , * .) | 10**; 15; 30** () 10*; 15*; 30* () | ||
∆ (*, ) | 7,5*; 15,0*; 30,0* () 10,0** () | ||
☼ () | 50,0 () | ||
∆ () | 0,125**; 0,25 () | ||
** | 0,5; 1,0; 2,5 () | 1 /; 3 / () | |
**∆ () | 1,0 () | ||
∆ (*, -) | 15; 30 () | ||
☼ (*, , , ** .) | 5; 10; 25* (, **) 5*; 10*; 25* () | 100 /2 * () | |
*∆ () | 1; 2 () |
(). . .
|
|
. . .
(*, *) (*, **).
. . .
☼ . . .
∆ (). . .
* . . .
** / . . .
, - , (). , - (. . ). . : ) ; ) ; ) ; ) (LD50:ED50). , , , . . , (, , , , ) . 1- . , .
|
|
.
. , , 20 , . , (6 ) . . . . , . , , , , . , , . :
1. , .
2. .
3. ( , , ).
4. (, , , , , ).
5. , , (, ) .
6. ( ).
7. , .
8. ; , , .
.
. , .
.
, , , , . , . , . , .
|
|
. , , ( ), , . . , , , . , , , (. . ), . , , , , , , , .
IV (DSM-IV) , . DSM-III DSM-IV ( ) , . , , , . , , . , , . . (, ), . , , , . , , , , , , , , , . , (, -), , , , .
. , . , , , . , , .[59] , .
|
|
. . 1-3 , (. 5.2). , .
5.2.
()*** | () | |||
(, .) | 0,5 | 6-20 | ||
(, , , .) | 5,0 | 30-100 | ||
* () | 15,0 | - | 50-160 | |
(*, , , .) | 0,25 | 18-50 | ||
() | 7,5 | 30-100 | ||
(*, , , .) | 1,0 | 10-20 | ||
** (, .) | 10,0 | - | 50-120 | |
(*, *, ) | 15,0** | 2-3 | ||
(, .) | 10,0 | 30 | ||
(, .) | 15,0 | - | 8-12 | |
(, *) | 30,0**** | 8-20 | ||
** () | 200,0 | - | 8-12 | |
() | 0,25 | 1,5-5 | ||
** | 1,0 | 20 | ||
** () | 1,0 | 20 | ||
(*, -) | 30,0 | - | 50-160 | |
(*, , , ** . | 10,0 | 30-100 | ||
* () | 2,0 | 10-24 |
, . ( ). , . .
. .
* . . .
** / . . .
*** , -, , ( ) . . .
**** , 10-20 /. . .
(. 5.2). , , . , . , (. 5.1). , , , , . , , . , . , . . . , , , . , , (, ) .
|
|
. 5.1. , . . . , , .
(. 5.2), . 1 per os.
. ( , )[60] , , . , . , , . , . . . , .
. . . , , , , , , , . , .
. . . , (. 2), . , , . (. ). .
( ). , (. 5.1). , .
. , , . : ) , ( , α, ); ) ( β ).
, , . . , , . , .
(. 5.3). (, ) ( , ). , , , .
5.3.